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Priapism is a urological emergency with multiple aetiologies including drug induced. Currently, there have been no reports of
priapism induced by the combination of ecstasy and marijuana. We speculated on the potential mechanisms for acute drug-
induced priapism resulting from ingestion of these two common illicit drugs.
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1. INTRODUCTION
Priapism is a urological emergency that, left untreated, may
lead to permanent damage to the corpora cavernosa result-
ing in erectile dysfunction. It is deﬁned as a persistent pe-
nile erection greater than four hours in duration, which is
unrelated to sexual stimulation or desire [1]. This condi-
tion can be divided into nonischaemic priapism (high-ﬂow)
and ischaemic (low-ﬂow) priapism. Nonischaemic priapism
is rare and often painless; it is thought to occur secondary
to the rupture of a cavernous artery resulting in unregu-
lated ﬂow into the lacunar spaces and commonly results
as a consequence of penile trauma or blunt perineal injury
[2]. Ischaemic priapism is usually due to unremitting cor-
poreal veno-occlusion resulting in venous stasis within the
cavernous tissue and is associated with pain and tenderness.
Prolonged penile veno-occlusion can result in a comprised
ability to achieve an erection and penile ﬁbrosis [2].
We present a case of a previously well 52-year-old Cau-
casian male who presented to the department of emergency
medicine (DEM) with a four-day history of persistent erec-
tion following a night involving a sexual encounter and in-
gestion of ecstasy and marijuana. The next morning after his
sexualencounter,henoticedaprolongederection,whichwas
progressing in pain. He had taken only one portion of ec-
stasy and marijuana but was unable to quantify the dose. He
was not a regular user and had not used ecstasy or marijuana
for at least 12 months. He denied taking other oral, intra-
venous, or intracavernous drugs. Other known causes of pri-
apism were excluded. Two days after his sexual encounter, he
presented to his family physician for treatment. Initial man-
agement with oral pseudoephedrine (60mg) did not resolve
his priapism and a needle aspiration was performed 60 min-
utes later. However, these measures provided only minor re-
lief and he presented to DEM two days later.
Physical examination at DEM revealed an erect, swollen,
and tender penis. No other abnormalities were detected. De-
tumescence was achieved by the attending urologist via in-
sertion of 14-gauge cannulae in each side of the cavernosa.
No intracavernous medications were required. The patient
was discharged and referred to the medical unit to investi-
gate any medical causes of priapism. After four weeks, there
were no additional episodes of priapism. However, the pa-
tienthadreportedunsatisfactoryerectionssincetheincident,
which may have been a consequence of his four-day delayed
presentation.
2. DISCUSSION
We conducted a PubMed search with priapism and ecstasy
(3,4-methlyenedioxymethamphetamine (MDMA)) and/or
marijuana (cannabinoid, cannabis) and their pseudonyms.
Only one case report was found describing a chronic ecstasy
user who developed priapism following one month cessation
of ecstasy use [3]. The present case diﬀers from the latter
and suggests that acute priapism is possible from a single in-
gestion. No speciﬁc association between priapism and mar-
ijuana was found. Therefore, we aimed to explore the acute
relationship between priapism and ecstasy, marijuana, and2 Advances in Urology
thepossibility ofsynergistic activities betweenthesetwosub-
stances.
DublinandRazack[3]hypothesisedthatecstasy-induced
priapism is due to the eﬀect of ecstasy on serotonin (5-HT).
Chronic use of ecstasy results in reduced serotonin activi-
ties and serotonin-related components of brain neurons [4].
In general, serotonin pathways are considered to have an in-
hibitory eﬀect on sexual function [5], and chronic use of ec-
stasy may predispose males to priapism as a consequence of
the reduced sexual inhibition [3].
However, ecstasy ingestion often results in the release of
5-HT stores causing an acute rise in 5-HT concentration
[5]. Although 5-HT is primarily inhibitory, stimulation of
a subset of 5-HT receptors (i.e., 5-HT1C, 5-HT1D, 5-HT2C)
increases erections in animals [6]. Reports of priapism in-
duced by antidepressants such as trazodone [7], citalopram
[8], venlafaxine [9], and sertraline [10]a r ed o c u m e n t e d .T h e
proerection properties of 5-HT2C agonists are thought to be
parasympathetically mediated due to 5-HT2C receptors on
the visceromotor neurons of the sacral parasympathetic nu-
cleus of the spinal cord and on the dorsal gray commissure
and ventral horn motor neuron [11]. Therefore, acute ele-
vation of 5-HT induced by ecstasy ingestion may facilitate
erections.
Ecstasy ingestion also results in acute dopamine (DA)
release in the brain. This is thought to occur by diﬀusion
of ecstasy into cerebral neurons stimulating DA release [5].
Dopamine has facilitative eﬀects on sexual motivation, cop-
ulatory proﬁciency, and genital reﬂexes [11]. Clinically, lev-
adopa (a DA precursor) was found to increase nocturnal
erections in elderly males [12]. In addition, apomorphine,
a dopamine (D1,D 2) receptor agonist, has been observed to
produce erections in men that were not accompanied by sex-
ual arousal [13]. It is thought that the proerection proper-
ties of dopaminergic neurons occur by way of activating oxy-
tocinergic neurons in the paraventricular nuclei and that the
release of oxytocin produces erections [14].
Psychotropic drugs have been proposed as a causative
agent for priapism [1]. To date, no speciﬁc case of priapism
and marijuana was found in the literature. However, we have
speculated on potential cannabinoid properties that may fa-
cilitateerections.Cannabinoidscanpotentiallymodulateau-
tonomic blood outﬂow in both the central and peripheral
nervous systems, and also have direct eﬀects on the vascu-
lature. The most commonly researched cannabinoid recep-
tor is CB1 which is mostly found in the central nervous sys-
tem but is also present in the peripheral nervous system. In
rats, administered cannabinoids can cause hypotension and
bradycardia, which is thought to occur via inhibition of CB1
mediated prejunctional sympathetic outﬂow (inhibition of
norepinephrine), and increased vagal tone [15]. Increased
parasympathetic activity would promote penile tumescence
in the sexually aroused male. Furthermore, cerebral vasore-
laxation has been noted as a common eﬀect of CB1,C B 2,
and Δ9-tetrahydrocannabinol, the psychoactive ingredient of
marijuana. The vasorelaxation response has been suggested
to occur by way of hyperpolarization or repolarization via
inhibition of Ca2+ mobilization in vascular smooth muscle
[15]. However, the existence of cannabinoid receptors within
the human penile vasculature remains unknown.
Animal studies have produced contradictory ﬁndings.
Rat studies have demonstrated that cannabinoid receptor
antagonists have centrally mediated proerection properties
[16]. There is a paucity of studies investigating human erec-
tions and marijuana, and as a result there is insuﬃcient ev-
idence to suggest that marijuana will cause priapism in hu-
mans.
Synergist interactions between marijuana and ecstasy
have been observed suggesting that the endocannaboid sys-
tem is involved with the reinforcing properties of ecstasy
[17]. This relationship may be related to the involvement of
the cannabinoid in the interaction and regulation of DA syn-
thesis and turnover [18], which is considered the principle
neurotransmitter in the reinforcement pathway. Therefore, it
may be possible that the DA pathway is potentiated with a
combination of ecstasy and marijuana, which may also facil-
itate penile erections via DA stimulation of oxytocin.
3. CONCLUSION
We concluded that our patient suﬀered from an ecstasy-
inducedpriapism,mostlylikelymediatedviaacutelyelevated
dopamine and serotonin levels, and that the concentration
and interaction of these neurotransmitters may have been
augmented by marijuana. Cessation of these substances has
resulted in no further incidences of priapism. Therefore, il-
licit drug use is an important consideration for acute presen-
tations of priapism of unknown aetiology.
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